| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT00430040 Details | 2024-04-16 Interventional | 4 | 14 | Carvedilol Lisinopril Diabetes Mellit… Diabetes Mellit… Hypertension | - - | |||
| NCT05338580 Details | 2024-04-15 Interventional | 2 | 0 | Pembrolizumab Carcinoma Carcinoma, Tran… First-line Non-… First-line Urot… Second-line Mel… Second-line Uro… | Company Development strategy adjustment - | |||
| NCT04751370 Details | 2024-04-15 Interventional | 2 | - | Ipilimumab Nivolumab Adenocarcinoma Rectal Neoplasm… Locally Advance… Stage II Rectal… Stage III Recta… | Scheduled Interim Monitoring - | |||
| NCT06061523 Details | 2024-04-12 Interventional | 1 | 0 | Sotorasib Healthy Partici… | FDA and EMA agreed existing data are appropriate for approval and no further BE studies are
required. - | |||
| NCT06046482 Details | 2024-04-12 Interventional | 2 | - | Cetuximab Docetaxel Magrolimab Pembrolizumab Carcinoma Carcinoma, Squa… Squamous Cell C… Head Neck | PI Request - | |||
| NCT05712278 Details | 2024-04-12 Interventional | 1 | 7 | Cytarabine Fludarabine Leukemia Leukemia, Myelo… Leukemia, Myelo… Acute Myeloid L… | Sponsor's decision - | |||
| NCT05441930 Details | 2024-04-12 Interventional | 1 | 0 | Levofloxacin Cataract | Sponsor has suspended study to conserve capital for clinical development of lead asset - | |||
| NCT05429762 2022-001213-39 Details | 2024-04-12 Interventional | 1 | 56 | Maytansine Neoplasm | Tusamitamab ravtansine clinical development program is discontinued as CARMEN-LC03 trial did
not meet dual primary endpoint of improving progression-free survival. The decision is not
related to any safety concern. - | |||
| NCT04806178 Details | 2024-04-12 Interventional | 3 | 30 | BCG Vaccine Urinary Bladder… Bacillus Calmet… Bladder Cancer | Recruitment delay - | |||
| NCT05501665 Details | 2024-04-11 Interventional | 1/2 | - | Albumin-Bound P… Atezolizumab Carboplatin Cemiplimab Deoxyglucose Fluorodeoxygluc… Ipilimumab Nivolumab Paclitaxel Pembrolizumab Pemetrexed Carcinoma, Non-… Lung Neoplasms Lung Non-Small … Stage III Lung … Stage IV Lung C… | Pending a protocol amendment - | |||
| NCT05367401 2021-003263-10 Details | 2024-04-11 Interventional | 1/2 | 0 | Azacitidine Magrolimab Leukemia Leukemia, Myelo… Leukemia, Myelo… Myelodysplastic… Preleukemia Syndrome Acute Myeloid L… | waiting for update from Study Lead - | |||
| NCT04996004 Details | 2024-04-11 Interventional | 2 | 75 | Doxorubicin Leiomyosarcoma | Pfizer decided to terminate the study for administrative reasons. The termination was neither
due to safety concerns nor a request from the regulatory authorities. - | |||
| NCT04677855 Details | 2024-04-10 Interventional | 1 | 7 | Dutasteride Prednisone Prostatic Neopl… Prostate Cancer | Business Decision due to insufficient enrollment - | |||
| NCT04232306 Details | 2024-04-10 Interventional | 4 | 0 | Bupivacaine Pain, Postopera… Cesarean Sectio… Postoperative P… | Lack of resources to continue. - | |||
| NCT04057365 Details | 2024-04-10 Interventional | 2 | 15 | Nivolumab Biliary Tract N… Biliary Tract C… | Based on a Simon 2-stage design, this study did not meet response criteria to proceed to stage
2. - | |||
| NCT06068153 Details | 2024-04-09 Interventional | 2 | 0 | Lenvatinib Sotorasib Carcinoma, Non-… KRAS G12C Metastatic Non … | In view of the recent developments in the field (the increasing number of trials with new KRAS
inhibitors), the window of opportunity to answer the question raised in the AMBER trial was
missed. - | |||
| NCT05900674 Details | 2024-04-09 Interventional | 2 | 0 | Reteplase Ischemic Stroke Stroke | Sponsor - | |||
| NCT05554341 Details | 2024-04-09 Interventional | 2 | - | Albumin-Bound P… Nilotinib Paclitaxel Neoplasms Metastatic Mali… Refractory Mali… | Scheduled Interim Monitoring - | |||
| NCT04970719 Details | 2024-04-09 Interventional | 3 | [16 Refs] | 0 | Dexamethasone Janus Kinase In… Remdesivir COVID-19 Diabetes Mellit… COVID-19 Pneumo… | adequate cases were not available - | ||
| NCT04594811 2020-004175-41 Details | 2024-04-09 Interventional | 1 | 10 | Nivolumab Adenocarcinoma Esophageal Neop… Gastric or Gast… | Company strategic decision - |